reports
Akero Therapeutics to Present at the Jefferies Global Healthcare Confe...
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T. in New York, NY. A live webcast of the Company presentation will be available through the investor relations section of the Company'...
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation f...
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA’s determination that, based on an ass...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematu...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress 72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo; BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...
QNB Corp. Declares Q2 2024 Dividend
QNB Corp. Declares Q2 2024 Dividend Quakertown, PA, May 21, 2024 (GLOBE NEWSWIRE) -- QUAKERTOWN, PA (21 May 2024): At a regular meeting on May 21, The Board of Directors of QNB Corp. (OTC Bulletin Board: QNBC), parent company of QNB Bank, declared a quarterly cash dividend of $0.37 per share. The dividend is payable on June 28, 2024, to shareholders of record on June 14, 2024. QNB Corp. offers commercial and retail banking services through the twelve banking offices of its subsidiary, QNB Bank. QNB Corp.’s stock is traded in the over-the-counter market under the symbol “QNBC.” For mor...
Akero Therapeutics Reports First Quarter 2024 Financial Results and Pr...
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update -- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Ther...
- Laura Chico
Vera Therapeutics Provides Business Update and Reports First Quarter 2...
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2 trial expected in Q4 2024Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera Thera...
Akero Therapeutics to Present at the BofA Securities 2024 Health Care ...
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV. A live webcast of the Company presentation will be available through the investor relations section of the C...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the Compensation ...
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late...
QNB Corp. Reports Earnings For First Quarter 2024
QNB Corp. Reports Earnings For First Quarter 2024 QUAKERTOWN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- QNB Corp. (the “Company” or “QNB”) (OTC Bulletin Board: QNBC), the parent company of QNB Bank (the “Bank”), reported net income for the first quarter of 2024 of $2,594,000, or $0.71 per share on a diluted basis. This compares to net income of $4,118,000, or $1.15 per share on a diluted basis, for the same period in 2023. For the quarter ended March 31, 2024, the annualized rate of return on average assets and average shareholders’ equity was 0.59% and 6.53%, respectively, compared with 0...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
MDWD MEDIWOUND
LE LANDS' END INC.
HUBS HUBSPOT INC.
ARN ARNOLD GEORG AG
ANAB ANAPTYSBIO INC.
LILA LIBERTY LATIN AMERICA A
CRNX CRINETICS PHARMACEUTICALS
IIIV I3 VERTICALS
EVER EVERQUOTE
BDCO BLUE DOLPHIN ENERGY CO.
ABEO ABEO SA
LYFT LYFT
AEYE AUDIOEYE INC
CRMD CORMEDIX INC.
BDTX BLACK DIAMOND THERAPEUTICS
NRIX NURIX THERAPEUTICS
VITL VITAL FARMS
ALXO ALX ONCOLOGY HOLDINGS
TCRX TSCAN THERAPEUTICS INC
VERA VERA THERAPEUTICS INC
RXST RXSIGHT INC
MAX MEDIAALPHA INC
KRT KARAT PACKAGING INC
SERA SERA PROGNOSTICS INC
ELVN ONTO INNOVATION INC.
IZM IMARA INC
AVGD ICZOOM GROUP INC
ANG AV-GAD HLDGS LTD
EGIO ANGLOGOLD ASHANTI LIMITED
QTTB EDGIO INC.
PROP Q32 BIO INC
AKA PRAIRIE OPERATING CO.
IDR AKA BRANDS HOLDING CORP
1225 IDAHO STRATEGIC RESOURCES INC
AFRISTRAT INV HLDGS LTD
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VRTX VERTEX PHARMACEUTICALS INCORPORATED
SRPT SAREPTA THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
LL LUMBER LIQUIDATORS HOLDINGS INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
TSC TRISTATE CAPITAL HOLDINGS INC
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
PK PARK HOTELS & RESORTS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
OVID OVID THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
APLS APELLIS PHARMACEUTICALS
UBX UNITY BIOTECHNOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
ACET ADICET BIO INC
ASO ACADEMY SPORTS AND OUTDOORS
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
GBIO GENERATION BIO
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
SBTX SILVERBACK THERAPEUTICS
TNGX TANGO THERAPEUTICS
LBPH INC
IKNA LONGBOARD PHARMACEUTICALS
TCRX IKENA ONCOLOGY INC
VERA TSCAN THERAPEUTICS INC
HOWL VERA THERAPEUTICS INC
GLUE WEREWOLF THERAPEUTICS INC
AVTE MONTE ROSA THERAPEUTICS INC
CMPX AEROVATE THERAPEUTICS INC
GMTX COMPASS THERAPEUTICS
JANX GEMINI THERAPEUTICS INC
VIGL JANUX THERAPEUTICS INC
MLTX VIGIL NEUROSCIENCE INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
PEPG TYRA BIOSCIENCES INC
HR PEPGEN INC
EWTX HEALTHCARE TRUST OF AMERICA INC.
PRME EDGEWISE THERAPEUTICS INC
OCS PRIME MEDICINE INC
APGE OCULIS HOLDING AG
DNTH APOGEE THERAPEUTICS INC
DIANTHUS THERAPEUTICS INC
- Laura Chico
Vera Therapeutics Announces Two Oral Presentations at the 61st Europea...
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress 72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinic...
Universal Technical Institute Inc: 1 director
A director at Universal Technical Institute Inc sold 8,719 shares at 15.068USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- Wedbush Research
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
DPZ DOMINO'S PIZZA INC.
WSM WILLIAMS-SONOMA INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MGPI MGP INGREDIENTS INC.
KBH KB HOME
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FHN FIRST HORIZON CORPORATION
FB FACEBOOK INC. CLASS A
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
NFLX NETFLIX INC.
WD WALKER & DUNLOP INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
TENB TENABLE HOLDINGS
CHWY CHEWY INC. CLASS A
KDNY CHINOOK THERAPEUTICS
TVTX INC.
VOR TRAVERE THERAPEUTICS INC
MRVL VOR BIOPHARMA
STX MARVELL TECHNOLOGY INC
VERA SEAGATE TECHNOLOGY HLDGS PLC
ALIT VERA THERAPEUTICS INC
GFS FOLEY TRASIMENE ACQUISITION CORP
FUSN GLOBALFOUNDRIES INC
MLTX FUSION PHARMACEUTICALS INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
BROS TYRA BIOSCIENCES INC
DUTCH BROS INC
- Laura Chico
Vera Therapeutics Provides Business Update and Reports Fourth Quarter ...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet and extending the Company’s expected cash runway through potential approval and commercial launch ...
- Jonathan Moreland
TLYS TILLYS
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
CE CELANESE CORPORATION
BANC BANC OF CALIFORNIA INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
JFR NUVEEN FLOATING RATE INCOME FUND
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AYX ALTERYX
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
TALO TALOS ENERGY INC.
RBB RBB BANCORP
AXR AMREP
SKYE NEMUS BIOSCIENCE INC
ELAN ELANCO ANIMAL HEALTH INC.
ANIX ANIXA BIOSCIENCES
PAYS PAYSIGN INC
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
VTN INVESCO TRUST FOR INVESTMENT G
RZLT REZOLUTE
COOK INC.
MPA TRAEGER
FRST INC.
ASLE BLACKROCK MUNIYIELD PENNSYLVANIA FD
VPV PRIMIS FINANCIAL CORP
BPRN AERSALE CORP
CRBP INVESCO PA VALUE MUNI INC TST
LSXMK BANK OF PRINCETON
BHRB CORBUS PHARMACEUTICALS HOLDINGS INC.
MDRX LIBERTY SIRIUSXM GROUP
APRE BURKE HERBERT FINANCIAL SERVICES CORP
ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
INC.
APREA THERAPEUTICS INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.